Abstract 1440: Novel imipridone ONC206 suppresses ovarian cancer progression through modulating immune cell response

Advanced ovarian cancer (stages III and IV) is the most lethal gynecologic malignancy in the United States. Survival of this cancer has not improved to a major extent over the past decade. High-grade serous ovarian cancer (HGSC), in particular, is notable for its initial sensitivity to chemotherapy using platinum and taxane combination following debulking surgery. However, the vast majority of these cancers (>75-80%) recur within 12-24 months...